A clinico-aetiological and ultrasonographic study of Peyronie’s disease
Bhushan Kumar A B , Tarun Narang A , Somesh Gupta A and Madhu Gulati AA Department of Dermatology, Venereology and Leprology and Department of Radiology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India.
B Corresponding author. Email: kumarbhushan@hotmail.com
Sexual Health 3(2) 113-118 https://doi.org/10.1071/SH05031
Submitted: 28 May 2005 Accepted: 23 January 2006 Published: 26 May 2006
Abstract
Background: Peyronie’s disease is a localised connective tissue disorder that involves the tunica albuginea of the penis. Although long recognised as an important clinical entity of the male genitalia, the aetiology of this disease has remained poorly understood. Methods: The epidemiology and clinical presentation of Peyronie’s disease during a 10-year period was evaluated. Results: Forty-two men with Peyronie’s disease from Chandigarh, India were reviewed retrospectively. The prevalence of Peyronie’s patients was 1.97/1000 patients. Their ages ranged from 23 to 70 years. Most of them presented during the early phase of the disease. The most common presenting complaint was penile curvature in 34 (80.95%) followed by pain on erection in 28 (66.66%). History of penile trauma was revealed by four (9.52%) patients. Among the risk factors, hypercholesterolemia (60%), hypertension (33.3%) and asymptomatic hyperuricemia (28.34%) were the most common. Twenty-two patients with Peyronie’s disease were studied by ultrasonography. Ultrasonogram was more accurate than clinical assessment in delineating the extent of lesions. In one-third of the patients, sonography demonstrated the plaques to be more extensive than had been detected by clinical examination. Conclusions: The clinical symptoms and signs in our study were, in general, similar to those found in the previous studies. Higher incidence of hypertension and diabetes in patients with Peyronie’s disease may also be to an extent due to patients being in an older age group.
Additional keywords: aetiology, clinical presentation, penile ultrasound.
[1] Dunsmuir WD, Kirby RS. Francois de La Peyronie (1678–1747): the man and the disease he described. Br J Urol 1996; 78 613–22.
| PubMed |
[2] Ehrlich HP. Scar contracture: cellular and connective tissue aspects in Peyronie’s disease. J Urol 1997; 157 316–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[3] Brock G, Hsu GL, Nunes L, von Heyden B, Lue TF. The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol 1997; 157 276–81.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[4] Devine CJ, Somers KD, Jordan GH, Schlossberg SM. Proposal: trauma as the cause of the Peyronie’s lesion. J Urol 1997; 157 285–90.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[5] Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 1997; 158 1388–90.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[6] Ralph DJ, Schwartz G, Moore W, Pryor J, Ebringer A, Botazzo G. The genetic and bacteriological aspects of Peyronie’s disease. J Urol 1997; 157 291–4.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[7] Chilton CP, Westwood WM, Pryor JP. Factors associated in the aetiology of Peyronie’s disease. Br J Urol 1982; 54 748–50.
| PubMed |
[8] Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie’s disease. J Urol 2002; 168 1075–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[9] Schneider HJ, Rugendorff EW, Ro¨hrborn C. Pathogenesis, diagnosis and therapy of Induratio penis plastica (IPP). Int Urol Nephrol 1985; 17 235–44.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[10] Devine CJ. Editorial International conference on Peyronie’s disease. J Urol 1997; 157 272–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[11] Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, Klotz T, et al. — Epidemiology of Peyronie’s disease. Int J Impot Res 2002; 14 379–83.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[12] Lindsay MB, Schain DM, Grambasch P. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991; 146 1007–9.
| PubMed |
[13] Gelbard MK, Dorey F, James K. The natural history of Peyronie’s disease. J Urol 1990; 128 1376–9.
[14] Bystrom J, Rubio C. Induratio penis plastica: clinical features and aetiology. Scand J Urol Nephrol 1976; 10 12–20.
| PubMed |
[15] Furey CA. Peyronie’s disease: a treatment by the local injection of meticortelone and hydrocortisone. J Urol 1957; 55 251–66.
[16] Hinman F. Etiologic factors in Peyronie’s disease. Urol Int 1980; 35 407.
| PubMed |
[17] Somers KD, Dawson DM. Fibrin deposition in Peyronie’s disease plaque. J Urol 1997; 157 311–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[18] Davis CJ. The microscopic pathology of Peyronie’s disease. J Urol 1997; 157 282–4.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[19] Jalkut M, Gonzalez-Cadavid N, Rajfer J. Peyronie’s Disease: A Review. Rev Urol 2003; 5 142–8.
[20] Lyles KW, Gold DT, Newton RA, Parekh S, Shipp KM, Pieper CF, et al. Peyronie’s disease is associated with Paget’s disease of bone. J Bone Miner Res 1997; 12 929–34.
| PubMed |
[21] Ling RS. The genetic factor in Dupuytren’s disease. J Bone Joint Surg. 1963; 45 709–18.
[22] Schiavino D, Sasso F, Nucera E, Alcini E, Gulino G, Milani A, Patriarca G. Immunologic findings in Peyronie’s disease: a controlled study. Urology 1997; 50 764–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[23] Stewart S, Malto M, Sandberg L, Colburn K. Increased serum levels of anti-elastin antibodies in patients with Peyronie’s disease. J Urol 1994; 152 105–6.
| PubMed |
[24] Ģulha M, Alici B, Acar O, Mutlu N, Gökalp A. The relationship between diabetes mellitus, impotence and veno-occlusive dysfunction in Peyronie’s disease patients. Urol Int 1998; 60 101–4.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[25] Carrieri MP. A case – control study on risk factors for Peyronie’s disease. J Clin Epidemiol 1998; 51 511–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[26]
[27] Smith BH. Subclinical Peyronie’s disease. Am J Clin Path 1969; 52 385–90.
| PubMed |
[28] Balconi G, Angeli E, Nessi R, de Flaviis L. Ultrasonographic evaluation of Peyronie’s disease. Urol Radiol 1988; 10 85–8.
| PubMed |
[29] Muralidhar S, Gulati M, Kumar B, Sharma SK, Suman K, Roy PB. An ultrasonographic study of Peyronie’s disease. Australas Radiol 1996; 40 106–8.
| PubMed |
[30] Levine LA. Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol 1997; 158 1395–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[31] Teloken C, Rhoden EL, Grazziotin TM, Da Ros C, Sogari P, Souto C. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol 1999; 162 2003–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[32] Benson RC, Knoll LD, Furlow WL. Interferon alpha2b in the treatment of Peyronie’s disease. J Urol 1991; 145 1342.
[33] Ralph DJ, Al-Akraa M, Pryor JP. The Nesbit operation for Peyronie’s disease: 16-year experience. J Urol 1995; 154 1362–3.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[34] Khope SSP, Sirsat A. Corporoplasty with Saphenous Venous Patch Graft for Peyronie’s Disease. J Indian Med Assoc 2004; 102 265–6.
